Opdivo nivolumab regulatory update

The European Commission approved Opdivo nivolumab from Bristol-Myers to treat unresectable or metastatic melanoma in adults, regardless of BRAF status. Last month, EMA’s CHMP also recommended approval of the human IgG4 mAb against PD-1 to treat locally advanced or metastatic squamous non-small cell lung cancer (NSCLC) after prior chemotherapy. ...